Nuclear export inhibitors avert progression in preclinical models of inflammatory demyelination

Nature Neuroscience

Volumn 18, Issue 4, 2015, Pages 511-520

  Haines, Jeffery D ^a   Herbin, Olivier ^a   De La Hera, Belén ^a   Vidaurre, Oscar G ^a   Moy, Gregory A ^a   Sun, Qingxiang ^b   Fung, Ho Yee Joyce ^b   Albrecht, Stefanie ^c   Alexandropoulos, Konstantina ^a   McCauley, Dilara ^d   Chook, Yuh Min ^b   Kuhlmann, Tanja ^c   Kidd, Grahame J ^e   Shacham, Sharon ^d   Casaccia, Patrizia ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^d Karyopharm Therapeutics   (United States)

^e LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EXPORTIN 1; KAINIC ACID; KPT 276; KPT 350; NEUROPROTECTIVE AGENT; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG; ACRYLAMIDE DERIVATIVE; CELL RECEPTOR; EXPORTIN 1 PROTEIN; KARYOPHERIN; KPT-276; THIAZOLE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATTENUATION; CATALYSIS; CELL CYCLE; CELL NUCLEUS; CELL PROLIFERATION; CONTROLLED STUDY; CRYOPRESERVATION; CYTOPLASM; CYTOSKELETON; DEMYELINATION; DISEASE COURSE; DRUG EFFICACY; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; FEMALE; GENE EXPRESSION; HUMAN; IMMUNOCOMPETENT CELL; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; MALE; MOLECULE; MOUSE; NERVE CELL CULTURE; NERVE FIBER; NEUROPROTECTION; NONHUMAN; NUCLEAR EXPORT SIGNAL; PARALYSIS; PRIORITY JOURNAL; RAT; ACTIVE TRANSPORT; ANIMAL; ANTAGONISTS AND INHIBITORS; AXON; C57BL MOUSE; CELL CULTURE; DISEASE MODEL; DRUG EFFECTS; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; GENETICS; KNOCKOUT MOUSE; METABOLISM; PATHOLOGY; PRECLINICAL STUDY; PROTEOMICS; SPRAGUE DAWLEY RAT; TREATMENT OUTCOME;

ACRYLAMIDES; ACTIVE TRANSPORT, CELL NUCLEUS; ANIMALS; AXONS; CELL NUCLEUS; CELLS, CULTURED; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; DRUG EVALUATION, PRECLINICAL; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; FEMALE; KARYOPHERINS; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NEUROPROTECTIVE AGENTS; PROTEOMICS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, CYTOPLASMIC AND NUCLEAR; THIAZOLES; TREATMENT OUTCOME;

EID: 84925814996     PISSN: 10976256     EISSN: 15461726     Source Type: Journal    
DOI: 10.1038/nn.3953     Document Type: Article

References (50)

1. Trapp, B.D. et al. Axonal transection in the lesions of multiple sclerosis. N. Engl. J. Med. 338, 278-285 (1998).
2. Ferguson, B., Matyszak, M.K., Esiri, M.M. & Perry, V.H. Axonal damage in acute multiple sclerosis lesions. Brain 120, 393-399 (1997).
3. Nikić, I. et al. A reversible form of axon damage in experimental autoimmune encephalomyelitis and multiple sclerosis. Nat. Med. 17, 495-499 (2011).
4. Kim, J.Y. et al. HDAC1 nuclear export induced by pathological conditions is essential for the onset of axonal damage. Nat. Neurosci. 13, 180-189 (2010).
5. Dormann, D. et al. ALS-associated fused in sarcoma (FUS) mutations disrupt Transportin-mediated nuclear import. EMBO J. 29, 2841-2857 (2010).
6. Zhang, Z.C. & Chook, Y.M. Structural and energetic basis of ALS-causing mutations in the atypical proline-tyrosine nuclear localization signal of the Fused in Sarcoma protein (FUS). Proc. Natl. Acad. Sci. USA 109, 12017-12021 (2012).
7. Hutten, S. & Kehlenbach, R.H. CRM1-mediated nuclear export: to the pore and beyond. Trends Cell Biol. 17, 193-201 (2007).
8. Xu, D., Farmer, A. & Chook, Y.M. Recognition of nuclear targeting signals by Karyopherin-beta proteins. Curr. Opin. Struct. Biol. 20, 782-790 (2010).
9. Xu, D., Grishin, N.V. & Chook, Y.M. NESdb: a database of NES-containing CRM1 cargoes. Mol. Biol. Cell 23, 3673-3676 (2012).
10. Fung, H.Y. & Chook, Y.M. Atomic basis of CRM1-cargo recognition, release and inhibition. Semin. Cancer Biol. 27, 52-61 (2014).
11. Iqbal, K., Alonso Adel, C. & Grundke-Iqbal, I. Cytosolic abnormally hyperphosphorylated tau but not paired helical flaments sequester normal MAPs and inhibit microtubule assembly. J. Alzheimers Dis. 14, 365-370 (2008).
12. Alami, N.H. et al. Axonal transport of TDP-43 mRNA granules is impaired by ALS-causing mutations. Neuron 81, 536-543 (2014).
13. Lagier-Tourenne, C., Polymenidou, M. & Cleveland, D.W. TDP-43 and FUS/TLS: emerging roles in RNA processing and neurodegeneration. Hum. Mol. Genet. 19, R46-R64 (2010).
14. Winton, M.J. et al. Disturbance of nuclear and cytoplasmic TAR DNA-binding protein (TDP-43) induces disease-like redistribution, sequestration, and aggregate formation. J. Biol. Chem. 283, 13302-13309 (2008).
15. Kawai, Y., Garduno, L., Theodore, M., Yang, J. & Arinze, I.J. Acetylation-deacetylation of the transcription factor Nrf2 (nuclear factor erythroid 2-related factor 2) regulates its transcriptional activity and nucleocytoplasmic localization. J. Biol. Chem. 286, 7629-7640 (2011).
16. Niture, S.K., Jain, A.K., Shelton, P.M. & Jaiswal, A.K. Src subfamily kinases regulate nuclear export and degradation of transcription factor Nrf2 to switch off Nrf2-mediated antioxidant activation of cytoprotective gene expression. J. Biol. Chem. 286, 28821-28832 (2011).
17. Linker, R.A. et al. Fumaric acid esters exert neuroprotective effects in neuroinfammation via activation of the Nrf2 antioxidant pathway. Brain 134, 678-692 (2011).
18. Jain, A.K., Bloom, D.A. & Jaiswal, A.K. Nuclear import and export signals in control of Nrf2. J. Biol. Chem. 280, 29158-29168 (2005).
19. Kudo, N. et al. Leptomycin B inactivates CRM1/exportin 1 by covalent modifcation at a cysteine residue in the central conserved region. Proc. Natl. Acad. Sci. USA 96, 9112-9117 (1999).
20. Sun, Q. et al. Nuclear export inhibition through covalent conjugation and hydrolysis of Leptomycin B by CRM1. Proc. Natl. Acad. Sci. USA 110, 1303-1308 (2013).
21. Lapalombella, R. et al. Selective inhibitors of nuclear export show that CRM1/XPO1 is a target in chronic lymphocytic leukemia. Blood 120, 4621-4634 (2012).
22. Etchin, J. et al. Antileukemic activity of nuclear export inhibitors that spare normal hematopoietic cells. Leukemia 27, 66-74 (2013).
23. Recks, M.S. et al. Early axonal damage and progressive myelin pathology defne the kinetics of CNS histopathology in a mouse model of multiple sclerosis. Clin. Immunol. 149, 32-45 (2013).
24. Sakakibara, K. et al. CBS9106 is a novel reversible oral CRM1 inhibitor with CRM1 degrading activity. Blood 118, 3922-3931 (2011).
25. Bloss, E.B. & Hunter, R.G. Hippocampal kainate receptors. Vitam. Horm. 82, 167-184 (2010).
26. Basso, D.M. et al. Basso Mouse Scale for locomotion detects differences in recovery after spinal cord injury in fve common mouse strains. J. Neurotrauma 23, 635-659 (2006).
27. Merkler, D., Ernsting, T., Kerschensteiner, M., Bruck, W. & Stadelmann, C. A new focal EAE model of cortical demyelination: multiple sclerosis-like lesions with rapid resolution of infammation and extensive remyelination. Brain 129, 1972-1983 (2006).
28. Chaudhary, P. et al. Lipoic Acid reduces infammation in a mouse focal cortical experimental autoimmune encephalomyelitis model. Neurology 82, P1.221 (2014).
29. Li, A. et al. Upregulation of CRM1 relates to neuronal apoptosis after traumatic brain injury in adult rats. J. Mol. Neurosci. 51, 208-218 (2013).
30. Mastroeni, D. et al. Reduced RAN expression and disrupted transport between cytoplasm and nucleus; a key event in Alzheimer's disease pathophysiology. PLoS ONE 8, e53349 (2013).
31. Nagara, Y. et al. Impaired cytoplasmic-nuclear transport of hypoxia-inducible factor-1alpha in amyotrophic lateral sclerosis. Brain Pathol. 23, 534-546 (2013).
32. Dormann, D. & Haass, C. TDP-43 and FUS: a nuclear affair. Trends Neurosci. 34, 339-348 (2011).
33. Kim, J.Y. & Casaccia, P. HDAC1 in axonal degeneration: a matter of subcellular localization. Cell Cycle 9, 3680-3684 (2010).
34. Zhang, J. & Herrup, K. Nucleocytoplasmic Cdk5 is involved in neuronal cell cycle and death in post-mitotic neurons. Cell Cycle 10, 1208-1214 (2011).
35. Sultan, A. et al. Nuclear tau, a key player in neuronal DNA protection. J. Biol. Chem. 286, 4566-4575 (2011).
36. Ke, Y.D. et al. Tau-mediated nuclear depletion and cytoplasmic accumulation of SFPQ in Alzheimer's and Pick's disease. PLoS ONE 7, e35678 (2012).
37. Aggarwal, A. & Agrawal, D.K. Importins and exportins regulating allergic immune responses. Mediators Infamm. 2014, 476357 (2014).
38. Pemberton, L.F. & Paschal, B.M. Mechanisms of receptor-mediated nuclear import and nuclear export. Traffc 6, 187-198 (2005).
39. Shriver, L.P. & Dittel, B.N. T-cell-mediated disruption of the neuronal microtubule network: correlation with early reversible axonal dysfunction in acute experimental autoimmune encephalomyelitis. Am. J. Pathol. 169, 999-1011 (2006).
40. Goldmann, T. & Prinz, M. Role of microglia in CNS autoimmunity. Clin. Dev. Immunol. 2013, 208093 (2013).
41. Campbell, G.R. & Mahad, D.J. Mitochondria as crucial players in demyelinated axons: lessons from neuropathology and experimental demyelination. Autoimmune Dis. 2011, 262847 (2011).
42. Stankiewicz, J.M., Kolb, H., Karni, A. & Weiner, H.L. Role of immunosuppressive therapy for the treatment of multiple sclerosis. Neurotherapeutics 10, 77-88 (2013).
43. Tedeholm, H. et al. Time to secondary progression in patients with multiple sclerosis who were treated with frst generation immunomodulating drugs. Mult. Scler. 19, 765-774 (2013).
44. Rawji, K.S. & Yong, V.W. The benefts and detriments of macrophages/microglia in models of multiple sclerosis. Clin. Dev. Immunol. 2013, 948976 (2013).
45. Koyama, M. & Matsuura, Y. An allosteric mechanism to displace nuclear export cargo from CRM1 and RanGTP by RanBP1. EMBO J. 29, 2002-2013 (2010).
46. Vaguine, A.A., Richelle, J. & Wodak, S.J. SFCHECK: a unifed set of procedures for evaluating the quality of macromolecular structure-factor data and their agreement with the atomic model. Acta Crystallogr. D Biol. Crystallogr. 55, 191-205 (1999).
47. Bernard, C.C. et al. Myelin oligodendrocyte glycoprotein: a novel candidate autoantigen in multiple sclerosis. J. Mol. Med. 75, 77-88 (1997).
48. Stoppini, L., Buchs, P.A. & Muller, D. A simple method for organotypic cultures of nervous tissue. J. Neurosci. Methods 37, 173-182 (1991).
49. Vidaurre, O.G. et al. Cerebrospinal fuid ceramides from patients with multiple sclerosis impair neuronal bioenergetics. Brain 137, 2271-2286 (2014).
50. La Cour, T. et al. Analysis and prediction of leucine-rich nuclear export signals. Protein Eng. Des. Sel. 17, 527-536 (2004).